---
title: "HEPA.US (HEPA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HEPA.US/news.md"
symbol: "HEPA.US"
name: "HEPA.US"
parent: "https://longbridge.com/en/quote/HEPA.US.md"
datetime: "2026-05-21T10:36:29.448Z"
locales:
  - [en](https://longbridge.com/en/quote/HEPA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HEPA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HEPA.US/news.md)
---

# HEPA.US (HEPA.US) — Related News

### [Hepion Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286466673.md)
*2026-05-14T20:50:35.000Z*
### [Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% Stake](https://longbridge.com/en/news/284943693.md)
*2026-05-01T21:36:01.000Z*
> Vincent LoPriore has disclosed a 21.46% stake in Hepion Pharmaceuticals, Inc., filed on May 1, 2026. This stake includes

### [Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04](https://longbridge.com/en/news/283723406.md)
*2026-04-22T20:53:01.000Z*
> Hepion Pharmaceuticals has raised $700,000 through a private placement of 17.5 million shares at $0.04 each. The transac

### [Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions | HELP Stock News](https://longbridge.com/en/news/283351153.md)
*2026-04-20T04:15:46.000Z*
> Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Me

### [Hepion Pharmaceuticals 2025 10-K: $0 Revenue, $(0.88) EPS on $(8.28) M Net Loss](https://longbridge.com/en/news/278862251.md)
*2026-03-12T10:15:00.000Z*
> Hepion Pharmaceuticals reported no revenue for 2025, with a net loss of $(8.28) million or $(0.88) per share, despite na

### [Hepion Pharmaceuticals | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/278860600.md)
*2026-03-12T10:08:20.000Z*